Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
12-Month Double-Blind Placebo-Controlled Trial of LMTM in Behavioral Variant Frontotemporal Dementia
2011-005529-34Phase 3Completed
- Sponsor
- TauRx Therapeutics Ltd
- Start
- Aug 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in frontotemporal dementia (FTD) comparing LMTM with Placebo (2 arms). Primary endpoint: Primary efficacy endpoints. Started Aug 2012; status: completed.
02
Drugs
hydromethylthionine mesylate
03
Conditions
frontotemporal dementia (FTD)
Beyond the preview
Go deeper on 2011-005529-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005529-34.